Comment: Neuroleptic Malignant Syndrome Versus Serotonin Syndrome: The Search for a Diagnostic Tool

Pelonero AL , Levenson JL , Pandurangi AK . Neuroleptic malignant syndrome: a review. Psychiatr Serv 1998; 49:1163–72.

Davis JM , Caroff SN , Mann SC . Treatment of neuroleptic malignant syndrome. Psychiatr Ann 2000; 30:325–31.

Woodbury MM , Woodbury MA . Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 1992; 31:1161–4.

Taylor MA , Fink M . Catatonia in psychiatric classification: a home of its own. Am J Psychiatry 2003; 160:1233–41.

Reulbach U , Dütsch C , Biermann T . Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007; 11:R4.

Sakkas P , Davis JM , Janicak PG , Wang ZY . Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull 1991; 27:381–4.

Rosenberg MR , Green M . Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med 1989; 149:1927–31.

Tadke RR , Suryavanshi P . Use of intravenous valproate in a patient with neuroleptic malignant syndrome. J Neuropsych Clin N 2006; 18:131–2.

Trollor JN , Chen X , Sachdev PS . Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23:477–92.

Strawn JR , Keck PE Jr , Caroff SN . Neuroleptic malignant syndrome. Am J Psychiat 2007; 164:870–6.

Antipsychotics. Hoffman RS , Nelson LS , Howland MA , Lewin NA , Flomenbaum NE , Goldfrank LR eds. In: Goldfrank's manual of toxicologic emergencies. 1st ed. New York: McGraw-Hill, 2007: 583–90.